X4 Pharmaceuticals (XFOR) Capital Expenditures Growth (1y) (2018 - 2024)
X4 Pharmaceuticals (XFOR) Capital Expenditures Growth (1y) (2018 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 143.40% |
| 10 | X4 Pharmaceuticals | 165.58 Mn | -51.47 Mn | 2.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 1,588.89% |
| Mar 31, 2024 | 555.56% |
| Jun 30, 2023 | -123.68% |
| Mar 31, 2023 | -59.09% |
| Dec 31, 2022 | 161.54% |
| Sep 30, 2022 | -98.50% |
| Jun 30, 2022 | 107.66% |
| Mar 31, 2022 | -95.56% |
| Dec 31, 2021 | 101.88% |
| Sep 30, 2021 | -59.54% |
| Jun 30, 2021 | -5,611.11% |
| Mar 31, 2021 | -10.63% |
| Dec 31, 2020 | -931.33% |
| Sep 30, 2020 | 1,737.04% |
| Jun 30, 2020 | -10.00% |
| Sep 30, 2019 | 400.00% |
| Sep 30, 2018 | -250.00% |